Increased Demand Drives Queensland Compound Library Expansion
News Jul 06, 2009
Queensland Compound Library (QCL) has announced the acquisition and instalment of a third comPOUND® sample store from TTP LabTech Ltd. The purchasing of a third sample store, to integrate with their two existing comPOUND® sample stores and comPANION unit, comes a year after QCL became operational.
This new purchase reflects the success of QCL and the increased demand for compound management and logistics services now considered essential by Australian academia, medical research institutes, publicly funded research organizations and industry.
TTP LabTech’s comPOUND® sample store is a modular system, where stores can be linked in parallel. The self-contained modules can provide sample storage from ambient temperature down to -20° C depending on the user’s requirements. Sample tubes can be cherry picked from all linked stores, thereby allowing throughputs to increase as the library grows.
The comPANION unit connects comPOUND® stores to remote delivery or storage of individual microtubes from an expandable sample library. The QCL is the only dedicated automated compound management facility for tube and plate based systems in Australasia and was the first facility of its kind world-wide to fully integrate modular storage and liquid handling platforms. It is a national resource that services a range of organizations in the region and all of the comPOUND stores are run at a nominal temperature of 18° C.
The QCL’s third comPOUND® is a component of the Queensland Tropical Health Alliance, a collaboration between Griffith University, James Cook University, the Queensland Institute of Medical Research and the QLD State Government.
Dr David Camp of QCL commented ‘The QCL has grown extremely rapidly during the last year with the introduction of over 250,000 compounds, which has necessitated the purchase of another comPOUND® sample store. It has been extremely gratifying to see the successful integration of this third unit. As this was the first comPOUND® to be added since the original system was in place we were unsure how easy the process would be. However, installation went seamlessly with full integration of the new module achieved mid-way through the third day and sample processing up and running by the fourth.’
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE